ArticleInternational journal of antimicrobial agents2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
8 registry-linked trialsAbstract readEditorialComment
In one paragraph
Article in International journal of antimicrobial agents, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 8 registered trials, which are not on this map. Cited by 422 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
422citing papers in PubMed, 5 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Proflaxis for Healthcare Professionals Using Hydroxychloroquine Plus Vitamin Combining Vitamins C, D and Zinc During COVID-19 Pandemia: An Observational Study
Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care Due to Coronavirus Disease 2019 (COVID-19)- Randomised Controlled Trial
A Randomized Phase 2/3 Trial of Hydroxychloroquine In Covid-19 Kinetics
Clinical Trial Evaluating Safety and Efficacy of Hydroxychloroquine and Nitazoxanide Combination as Adjuvant Therapy in Covid-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope
Evaluation de l'efficacité et de la tolérance de Quinquina et d'un phytomédicament " ACAR " en Comparaison Avec l'Hydroxychloroquine Chez Des Adultes Malades de Covid-19 Sans symptômes
Évaluationefficacité et tolérance d'Une médication à Base de Cosphérunate et d'un phytomédicament Antiviral Par Voie Orale en Comparaison Avec un Traitement à Base d'Hydroxychloroquine Chez Des Adultes Malades Covid-19 Sans Complications
Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts
An aDaptive, multicEnter, rAndomized, Open-Label, Controlled Trial to Assess Effectiveness and Safety of Quinine Sulfate for COVID-19 in Hospitalized Adults
Who cites it
422 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Nanoparticles as an effective drug delivery system in COVID-19.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Pooled it
- Hydroxychloroquine for treatment of nonsevere COVID-19 patients: Systematic review and meta-analysis of controlled clinical trials.Journal of medical virology · 2021Pooled it
- Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.The Cochrane database of systematic reviews · 2021Pooled it
- Systematic review and meta-analysis of the effectiveness and safety of hydroxychloroquine in treating COVID-19 patients.Journal of the Chinese Medical Association : JCMA · 2021Pooled it
- The prognostic value of comorbidity for the severity of COVID-19: A systematic review and meta-analysis study.PloS one · 2021Pooled it
- Testing the feasibility of operationalizing a prospective, randomized trial with remote cardiac safety EKG monitoring during a pandemic.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2022Trial
- Therapeutic efficacy of macrolides in management of patients with mild COVID-19.Scientific reports · 2021Trial
- From Widespread Use to Loss of Effectiveness: The Consequences of Inappropriate Azithromycin Prescriptions During the COVID-19 Pandemic-A Systematic Review and Meta-Analysis.International journal of microbiology · 2026Review
- COVID-19 and a Tale of Three Drugs: To Repurpose, or Not to Repurpose-That Was the Question.Viruses · 2025Review
- Synthesis and anti-SARS-CoV-2 potential of novel coumarin hybrids: a combined wet/dry lab approach targeting MRSC advances · 2025Article
- Malabaricone C isolated from edible plants as a potential inhibitor of SARS-CoV-2 infection.Scientific reports · 2025Article
- Recent Developments in the Antimicrobial Potential of Some Nitrogenous Heterocycles and their SAR Studies: A Review.Current medicinal chemistry · 2025Review
- Efficacy and Safety of Antimalarial as Repurposing Drug for COVID-19 Following Retraction of Chloroquine and Hydroxychloroquine.Clinical pharmacology : advances and applications · 2025Review
- Repurposed Drugs during the Outbreak of Pandemic COVID-19: A Mini-Review on Their Molecular Structures and Hit-and-Trial Results.ACS omega · 2024Review
- A high-throughput response to the SARS-CoV-2 pandemic.SLAS discovery : advancing life sciences R & D · 2024Article
- Mechanisms Underlying the Effects of Chloroquine on Red Blood Cells Metabolism.International journal of molecular sciences · 2024Article
- Ethnic disparities and COVID-19 pneumonia in Ireland: a single-centre descriptive study of hospitalised patients in a tertiary university teaching hospital.Irish journal of medical science · 2024Article
- Article
- An approach to rapid distributed manufacturing of broad spectrum anti-viral griffithsin using cell-free systems to mitigate pandemics.New biotechnology · 2023Article
- The Penn Medicine COVID-19 Therapeutics Committee-Reflections on a Model for Rapid Evidence Review and Dynamic Practice Recommendations During a Public Health Emergency.Open forum infectious diseases · 2023Review
362 more citing papers are in PubMed but not listed here.
Corrections and comments
- Comment on
Authors and funding
5 authors.
Philippe ColsonAix-Marseille Université, Institut de Recherche pour le Développement (IRD), Assistance Publique-Hôpitaux de Marseille (AP-HM), MEPHI, 27 boulevard Jean Moulin, 13005 Marseille, France; IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France.
Jean-Marc RolainAix-Marseille Université, Institut de Recherche pour le Développement (IRD), Assistance Publique-Hôpitaux de Marseille (AP-HM), MEPHI, 27 boulevard Jean Moulin, 13005 Marseille, France; IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France.
Jean-Christophe LagierAix-Marseille Université, Institut de Recherche pour le Développement (IRD), Assistance Publique-Hôpitaux de Marseille (AP-HM), MEPHI, 27 boulevard Jean Moulin, 13005 Marseille, France; IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France.
Philippe BrouquiAix-Marseille Université, Institut de Recherche pour le Développement (IRD), Assistance Publique-Hôpitaux de Marseille (AP-HM), MEPHI, 27 boulevard Jean Moulin, 13005 Marseille, France; IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France.
Didier RaoultAix-Marseille Université, Institut de Recherche pour le Développement (IRD), Assistance Publique-Hôpitaux de Marseille (AP-HM), MEPHI, 27 boulevard Jean Moulin, 13005 Marseille, France; IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France. Electronic address: didier.raoult@gmail.com.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
CoronavirusHydroxychloroquineAdenosine MonophosphateAlanineBetacoronavirusChloroquineCoronavirus InfectionsCOVID-19PandemicsPneumonia, ViralSARS-CoV-2Adenosine MonophosphateAlanineChloroquineHydroxychloroquineremdesivir
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT04326725ClinicalTrials.gov
NCT04339816ClinicalTrials.gov
NCT04353271ClinicalTrials.gov
NCT04361318ClinicalTrials.gov
NCT04501965ClinicalTrials.gov
NCT04502342ClinicalTrials.gov
and 2 more above
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.